Back HIV/AIDS

HIV / AIDS

AIDS 2012: HPTN 052 Continues to Show Clinical Benefits of Earlier Antiretroviral Therapy

The HPTN 052 trial, best known for showing that early antiretroviral therapy (ART) can dramatically reduce the risk of HIV transmission within serodiscordant couples, also found that early treatment reduces the risk of clinical events and death, though the benefit was largely driven by extrapulmonary tuberculosis, researchers reported recently at the XIX International AIDS Conference (AIDS 2012) in Washington, DC.

alt

AIDS 2012: Expanded Access to HIV Treatment Lowered AIDS Deaths Worldwide

Many low- and middle-income countries have begun to devote significant resources towards HIV/AIDS treatment, matching wealthy international donor countries, according to a new report release by the United Nations Joint Programme on AIDS (UNAIDS) in advance of the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC. This increased funding has enabled an expansion of antiretroviral treatment that has helped reduced AIDS-related deaths by 100,000 over the past year.

AIDS 2012: Raltegravir Remains Effective and Well-tolerated at 5 Years

The HIV integrase inhibitor raltegravir (Isentress) continued to demonstrate good efficacy as part of a first-line antiretroviral regimen and had a consistently favorable safety profile at 240 weeks in the STARTMRK trial, researchers reported at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC.Another long-term analysis showed continued efficacy for treatment-experienced patients with extensive drug resistance.alt

AIDS 2012: Black Gay Men Have Higher HIV Rates Despite No Greater Risk Behavior

African-American gay and bisexual men in U.S. cities have a significantly higher likelihood of becoming infected with HIV despite the fact that they do not engage in more high-risk sex or drug use, according to studies presented at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC, and in an HIV-theme issue of The Lancet.

[Alan Guttirez from HIVandHepatitis.com interviews Gregorio Millett and Sheldon Fields about HIV disparities among black gay and bisexual men and how they might be overcome.]alt

AIDS 2012: Long-acting HIV Integrase Inhibitor S/GSK1265744 May Allow Monthly Dosing

A nano-suspension formulation of the next-generation integrase inhibitor S/GSK1265744 demonstrated a half-life 21 to 50 days after a single injection, suggesting that once-monthly or even less frequent dosing may be possible, according to a poster presentation at the XIX International AIDS Conference (AIDS 2012) recently held in Washington, DC.alt

AIDS 2012: Why Do Black Gay and Bisexual Men Have Higher HIV Rates? [VIDEO]

Several studies presented at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC, shed further light on disproportionately high rates of HIV prevalence and incidence among African-American men who have sex with men (MSM).alt

AIDS 2012: French Cohort Treated during Primary Infection Appears to Control HIV without ART

A group of French HIV patients known as the VISCONTI cohort, who started antiretroviral therapy (ART) during the earliest stage of infection, so far appear to be controlling the virus after interrupting treatment, researchers reported at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC.

alt